Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original human data synthesis
PubMed 41966639 · doi:10.1007/s40279-026-02437-0
What was done
This narrative review examined the pharmacological mechanisms, safety profiles, and regulatory status of approved and unapproved peptide therapies marketed for musculoskeletal healing and athletic performance (including AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-c, sermorelin, SS-31, tesamorelin, Tβ4, and TB-500). It also evaluated the influence of the placebo effect and social media, and provided a framework for clinicians counseling patients on these compounds.
What was found
The abstract reports no quantitative human trial data. It notes that while many unapproved peptides exhibit favorable tissue repair and metabolic effects in animal models, rigorous human safety and clinical efficacy data are scarce, creating potential for patient harm.
Why it matters
As gray-market peptide use expands among athletes and patients, this review outlines the mechanistic rationale, lack of human clinical trial validation, and safety risks to help clinicians guide evidence-based discussions.
Limits
As a narrative review, it lacks a systematic literature search, risk of bias assessment, or meta-analytic pooling. The abstract provides no sample sizes, effect estimates, or primary human trial results; evidence for most discussed agents remains limited to preclinical animal studies.
Cited by
- context Tesamorelin combined with ipamorelin can increase IGF-1 levels into the 380s or 390s ng/mL.